Typhoid Fever - Pipeline Review, H2 2019

Report / Search Code: RnM3727951  Publish Date: 05 September, 2019

Price
1-user PDF : $ 2000.0
1-5 User PDF : $ 4000.0
Enterprise PDF : $ 6000.0

Description:
Typhoid Fever - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H2 2019, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.
Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Unknown stages comprises 1, 2 and 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain contents / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Typhoid Fever - Overview
Typhoid Fever - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Typhoid Fever - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Typhoid Fever - Companies Involved in Therapeutics Development
Eubiologics Co Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Ology Bioservices Inc
Prokarium Ltd
Protein Potential LLC
Sanofi Pasteur SA
Shantha Biotechnics Pvt Ltd
Walvax Biotechnology Co Ltd
Typhoid Fever - Drug Profiles
(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(paratyphoid + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(rotavirus (virus like particle) + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(shigella + typhoid) (Bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhella - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ViCRM-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ViCRM-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Typhoid Fever - Dormant Projects
Typhoid Fever - Discontinued Products
Typhoid Fever - Product Development Milestones

Featured News & Press Releases

Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification

Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine

Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization

Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate

Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine

Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine

Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study

Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine